Permanent ~(125)I prostate brachytherapy for prostate cancer

XING Jin-chun,LIU Rong-fu,CHEN Bin,WANG Hui-qiang,ZHANG Kai-yan,YE You-xin,ZHUANG Xuan,YANG Yu-feng,ZHOU Xin,ZHENG Jia-xin,CHEN Shi-xin,ZHOU Zhong-quan
DOI: https://doi.org/10.3969/j.issn.1672-2019.2006.02.014
2006-01-01
Abstract:[Objective] To study the clinical significance of peranent 125I prostate brachytherapy for prostate cancer. [Methods] A total of 5 patinets of prostate cancer underwent 3-dimensional conformal brachytherapy with transperineal ultrasound-guide 125I seeds prostate implantation, of then 3 patinets with bone metastases. [Results] The mean number of 125I seeds implantated was 40. The mean operating time was 75 mins, and mean hospitalization was 6 d. All patients were followed up for 3 to 11 months with a mean of 5 months.3 cases had completed reaction; 1, partical reaction; 1, developed progressive disease. PSA progression-free survival rate was 80%. No severe complication occurred. [Conclusions] Brachytherapy with 125I seeds implantation guided by transrectal ultrasound is a safe, minimally invasive and effective treatment with low morbidity of complication for prostate cancer patients.
What problem does this paper attempt to address?